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Microcalcifications in breast cancer: novel insights into the
molecular mechanism and functional consequence of mammary
mineralisation
RF Cox1, A Hernandez-Santana2, S Ramdass1, G McMahon2, JH Harmey1 and MP Morgan*,1
1Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St Stephen’s Green, Dublin 2, Ireland; 2School of Chemical Sciences,
Dublin City University, Dublin 9, Ireland
BACKGROUND: Mammographic microcalcifications represent one of the most reliable features of nonpalpable breast cancer yet remain
largely unexplored and poorly understood.
METHODS: We report a novel model to investigate the in vitro mineralisation potential of a panel of mammary cell lines. Primary
mammary tumours were produced by implanting tumourigenic cells into the mammary fat pads of female BALB/c mice.
RESULTS: Hydroxyapatite (HA) was deposited only by the tumourigenic cell lines, indicating mineralisation potential may be associated
with cell phenotype in this in vitro model. We propose a mechanism for mammary mineralisation, which suggests that the balance
between enhancers and inhibitors of physiological mineralisation are disrupted. Inhibition of alkaline phosphatase and phosphate
transport prevented mineralisation, demonstrating that mineralisation is an active cell-mediated process. Hydroxyapatite was found to
enhance in vitro tumour cell migration, while calcium oxalate had no effect, highlighting potential consequences of calcium deposition.
In addition, HA was also deposited in primary mammary tumours produced by implanting the tumourigenic cells into the mammary
fat pads of female BALB/c mice.
CONCLUSION: This work indicates that formation of mammary HA is a cell-specific regulated process, which creates an osteomimetic
niche potentially enhancing breast tumour progression. Our findings point to the cells mineralisation potential and the
microenvironment regulating it, as a significant feature of breast tumour development.
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The appearance of mammographic mammary microcalcifications
is routinely used to detect breast cancer in its early stages allowing
more conservative therapy and better patient outcomes. Up to 50%
of all nonpalpable breast cancers are detected solely through
microcalcifications presenting during a mammogram scan (Gulsun
et al, 2003) and up to 93% of cases of ductal carcinoma in situ
(DCIS) present with microcalcifications (Hofvind et al, 2011).
There is mounting evidence to suggest that mammary micro-
calcifications are associated with a poorer prognosis for certain
breast cancer patients. Studies have shown that breast cancers
presenting with microcalcifications are more often associated with
lymph node invasion (Holme et al, 1993) and HER-2 positivity
(Seo et al, 2006; Wang et al, 2008). A study by Tabar et al (2004)
has investigated whether mammographic features of microcalcifi-
cations can be used to reliably predict the long-term outcome for
women with small (1–14mm) invasive breast cancers. A subgroup
of women within the study who presented with mammographic
casting-type calcifications was found to have unexpectedly poor
survival rates for this tumour-size category. Although this finding
has been the subject of some debate in the literature (James et al,
2003; Evans et al, 2006; Mansson et al, 2009), other research groups
have reported similar findings that support the work of Tabar et al
(Thurfjell et al, 2001; Peacock et al, 2004).
Mammary microcalcifications have been classified at a mole-
cular level and are distinguished by their physical and chemical
properties. Type I calcifications are composed of calcium oxalate
(CO), which are amber in colour, partially transparent and form
pyramidal structures with relatively planar surfaces. Type II
calcifications are composed of calcium phosphate, mainly
hydroxyapatite (HA), which are grey-white, opaque and form
ovoid or fusiform shapes with irregular surfaces (Frappart et al,
1984). Calcium oxalate has been shown to be associated with
benign lesions of the breast or at most non-invasive lobular
carcinoma in situ, whereas HA is associated with both benign and
malignant breast conditions (Bu¨sing et al, 1981; Frappart et al,
1984, 1986; Radi, 1989; Haka et al, 2002). It has been suggested that
HA calcifications formed in benign ducts contain smaller amounts of
protein and higher amounts of calcium carbonate than those formed
in malignant ducts (Haka et al, 2002). A more recent study supports
this concept and has also shown that the carbonate content of
HA decreases with increasing lesion grades (Baker et al, 2010).
Little research has been carried out to investigate the impact that
the presence of HA has within the tumour microenvironment,
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however, this group has previously reported on the biological
effects of exogenous HA on mammary cell lines. We have
previously shown that HA enhances the mitogenesis of mammary
cells, which may amplify the malignant process by aggravating
tumour growth (Morgan et al, 2001). Increased expression
of prostaglandin E2 was also found to be associated with HA
treatment (Morgan et al, 2001) and elevated levels of prostaglan-
dins are known to be a marker of high metastatic potential
(Rolland et al, 1980). The inflammatory cytokine IL-Ib was also
found to be upregulated in mammary cell lines in response to
exogenous HA, which could promote a pro-inflammatory micro-
environment (Cooke et al, 2003). HA was also shown to upregulate
a variety of matrix metalloproteinases (MMPs), which are known
to degrade the basement membrane allowing cancer cells to invade
into surrounding tissues (Morgan et al, 2001).
Despite the importance of mammary microcalcifications for the
early detection of breast cancer and the potential prognostic and
biological relevance, little research has been carried out to
investigate the molecular mechanisms involved in their formation.
In the past, mammary calcification has been considered a passive,
end stage process associated with cellular degeneration with no
tangible biological significance. However, studies in other cellular
systems have suggested that the mechanisms regulating patho-
logical mineralisation may be similar to those involved in
physiological mineralisation of bone (Giachelli, 2004; Kirsch,
2006; Shroff and Shanahan, 2007), which is widely considered to
be an active regulated process (Stein and Lian, 1993; Giachelli,
2005; Orimo, 2010). Breast cancer biopsies have been shown to
overexpress several bone matrix proteins, including bone sialo-
protein, osteopontin (OPN) and osteonectin. In addition, their
expression is associated with frequent microcalcification deposi-
tion in the breast lesions (Bellahcene et al, 1994; Bellahcene and
Castronovo, 1995). To date, no in vitro models of mammary
cell mineralisation exist to study the molecular mechanisms
involved in this process. The aim of this study was to establish
and characterise a reproducible in vitro model of mammary cell
mineralisation, from which the molecular mechanisms underlying
mammary mineralisation can begin to be elucidated.
MATERIALS AND METHODS
Cell lines and media
The murine mammary adenocarcinoma 4T1 cell line was generously
provided by Dr Fred Miller (Duke University, NC, USA) (Aslakson
and Miller, 1992). The murine mammary adenocarcinoma 4T1.2
cells that preferentially metastasis to bone, were a gift from Robin
Anderson (Peter MacCallum Cancer Centre, Australia) (Lelekakis
et al, 1999). The 4T1 and 4T1.2 cell lines were maintained in low
glucose DMEM, 10% FBS and 1% penicillin/streptomycin. The
MCF10a, Hs578T and Hs578Ts(i)8 cell lines were a gift from Dr
Susan McDonnell (University College Dublin, Ireland). The MCF10a
cells were maintained in DMEM/F-12, 5% horse serum, 0.5mgml–1
hydrocortisone, 100 ngml–1 cholera toxin, 0.2mgml–1 epidermal
growth factor, 10mgml–1 bovine insulin and 1% penicillin/
streptomycin. The Hs578T and Hs578Ts(i)8 cells (Hughes et al,
2008) were maintained in high glucose DMEM, 10% FBS, 10mgml–1
bovine insulin and 1% penicillin/streptomycin. All cell culture
reagents were purchased from Sigma-Aldrich (Arklow, Ireland) and
Biosera (East Sussex, UK).
Assessment of mineralisation in vitro
4T1, 4T1.2 and MCF10a cells were seeded into six-well culture
plates (day 1) at 1.5 105 cells per well and Hs578T and
Hs578Ts(i)8 cells were seeded at 7.5 104 cells per well. The
following day (day 0) the cells were treated with regular growth
media or an osteogenic cocktail (OC) (50 mgml–1 ascorbic acid,
10mM b-glycerophosphate (bG) ±107 M dexamethasone). The
effects of additional exogenous factors were also investigated
including inorganic phosphate (Pi) (10mM; Sigma-Aldrich, #30427
and #71496), phosphonoformic acid (PFA) (1mM; Sigma-Aldrich,
#79510), levamisole (100 mM; Sigma-Aldrich, #L9756), alkaline
phosphatase (ALP) (1Uml–1; Sigma-Aldrich, #79390), OPN
(0.5mgml– 1; R&D Systems Europe Ltd., Abingdon, UK, #109-OP)
and inorganic pyrophosphate (PPi) (3.5 mM; Sigma-Aldrich,
#P8010). Cells were grown for up to 28 days in a humidified
incubator at 37 1C and 5% CO2. Mineralisation was assessed using
alizarin red S staining, von Kossa staining, quantitative calcium
assay and Raman microspectroscopy, as described below.
Assessment of mineralisation in vivo
All mice were housed in a licensed biomedical facility (RCSI,
Beaumont Hospital) and had ad libitum access to food and water.
The animals were caged in groups of 5 or less and were
acclimatised to their environment for 1 week. Cages were kept
in an air-conditioned room (21–22 1C) and were on a 12-h light–
dark cycle. All procedures were subjected to institutional ethics
review and were carried out under the animal license guidelines of
the Department of Health and Children, Ireland and in accordance
with the UK Co-ordinating Committee on Cancer Research
guidelines for the welfare of animals in experimental neoplasia
(1998). 4T1.2 or 4T1 cells (5 104) were implanted into the
mammary fat pad of 10- to 12-week-old female BALB/c mice. Mice
were killed when tumours reached a mean tumour diameter
(square root of the product of length by breadth) of 17mm.
Tumours were excised, fixed in 10% paraformaldehyde and
embedded in paraffin wax. Mineralisation was assessed using
alizarin red S and von Kossa staining, as described below.
Histological staining
Cell monolayers were fixed with 10% formalin for 30min and
stained with alizarin red S (2%, pH 4.4) for 4min. For von
Kossa staining, silver nitrate (5%) was applied for 1 h under an
electric lamp followed by sodium thiosulphate (5%) treatment
for 2min. For paraffin-embedded tissue, serial sections (10mm)
were deparaffinised using xylene and rehydrated before
staining with alizarin red S, von Kossa (using nuclear fast red
counterstain) or haematoxylin and eosin (H&E). Samples were
then dehydrated, incubated with xylene (30min) and mounted
with DPX.
Quantitative o-cresolphthalein calcium assay
Calcium was extracted from cell monolayers by incubation with
nitric acid (1 M) for 1 h. The absorbance of the samples (70ml)
in combination with o-cresolphthalein (0.1mgml–1; 70 ml) and
2-amino-2-methyl-1-propanol (90mgml–1; 175ml) was read at
572 nm (Yavorskyy et al, 2010). A protein assay was carried out on
duplicate wells. Cells were harvested in RIPA lysis buffer (1 PBS;
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing 1%
protease inhibitor cocktail (Sigma-Aldrich, #P8340), stored on ice
for 1 h with occasional vortexing and centrifuged at 12 000 r.p.m.
for 20min. The supernatant was used for the BCA protein assay
(Novagen, Merck Group, Darmstadt, Germany), which was carried
out according to the manufacturer’s instructions.
Raman microspectroscopy
Cell monolayers were fixed with 100% methanol for 30min. Raman
spectra were acquired on a Witec Alpha 300 R microscope
(Ulm, Germany) equipped with a 532 nm Ar-Ion laser (B40mW)
with a spectral resolution of 3 cm1 using backscattering config-
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uration and a  100 objective (NA¼ 0.9). Point spectra were
acquired from areas of mineral deposition initially identified
visually using an optical image. Spectra were processed using
Witec Project v2.0 60 software. Measurements were taken from five
different points for each well, including biological repeats.
Real-time RT–PCR
RNA was extracted using trizol (Invitrogen, Life Technologies,
Carlsbad, CA, USA, #15596) and reverse transcribed using a
high-capacity cDNA reverse transcription kit (Applied Biosystems,
Life Technologies, #4368814). Real-time PCR was carried out using
the real-time PCR thermocycler (Applied Biosystems, 7500)
for ALP (Qiagen, West Sussex, UK, QT00157717), OPN (Qiagen,
QT00157724) and 18s (Qiagen, QT01036875) as an endogenous
control. Samples were heated at 95 1C for 15min, followed by a
second stage composed of 15 s at 94 1C, 30 s at 55 1C and 45 s at
72 1C, which was repeated 40 times.
Detection of ALP activity
Cells were harvested in a buffer (1% Triton X-100, 0.9% NaCl)
and kept on ice for 1 h with occasional vortexing. Samples were
centrifuged at 12 000 r.p.m. for 20min and the supernatant was
used for the ALP assay. Samples (50ml) and p-nitrophenyl
phosphate (100ml) were incubated at 37 1C for 30min and
absorbance was measured at 405 nm. The results were normalised
to protein content in the samples using the BCA protein assay
(Novagen), which was carried out according to the manufacturer’s
instructions.
An ALP stain was also used. Cell monolayers were fixed using
100% methanol for 30min. Tris-HCl (pH 8.5) containing naphthol
AS-MX phosphate (1mgml–1) and fast red violet LB (0.6mgml–1)
was added to each well, which were incubated at 37 1C for 45min.
Images were recorded at  100 magnification using the Nikon
eclipse TS100 inverted light microscope (Nikon, Surrey, UK).
Assessing migration by scratch wound assay
4T1 cells were seeded into six-well plates (7 105 cells per well)
and the following day multiple scratch wounds were created in the
monolayers. In the presence of 0.5% FBS media, the following
treatments were added; 1.8–10mM calcium, 0–10mM bG,
0–72 mg cm–2 CO monohydrate (Sigma-Aldrich, #21201) or
0–72 mg cm–2 HA (Sigma-Aldrich, #677418). The HA and CO
crystals were sterilised by heating at 200 1C for 90min and
sonicated briefly before their use. The cells were kept in a
humidified incubator at 37 1C containing 5% CO2. Tiff images of
the scratch wound assays taken at  100 magnification at 0, 24 and
48 h were imported into Scion Image software (Scion Corporation
Ltd, Frederick, MD, USA), which is used to generate wound size
measurements from still images (McSherry et al, 2011). The mean
closure of the wound was calculated from six individual
measurements for each wound at each time point. This process
was carried out for all biological repeats. The day 0 scratches were
designated as 100% open. From this, the % closure for all scratches
was calculated. The % closure represents the distance that the cells
migrated into the scratch wound area over time. Results are
presented as mean % closure ±s.e.m.
Statistical analysis
All statistical analysis was carried out using GraphPad Prism
5 software (La Jolla, CA, USA). A one-way analysis of variance
(ANOVA) was used to analyse multiple treatment groups. A two-
way ANOVA was used to analyse multiple treatments over multiple
time points. Post-hoc analysis was carried out when statistical
significance (Po0.05) was detected.
RESULTS
In vitro mineralisation of metastatic 4T1 mammary
adenocarcinoma cells
In order to study the molecular mechanisms of mammary
mineralisation, it was necessary to first establish and characterise
a reproducible in vitro model. The highly metastatic mouse
mammary 4T1 cell line was grown in culture plates for up to 28
days in the presence of regular growth media (control), an OC
(10mM bG and 50 mgml–1 ascorbic acid in regular growth media)
or the OC containing 107 M dexamethasone (OC&dex). Cell
monolayers were stained with alizarin red S and von Kossa to
assess mineralisation and observed under the light microscope at
 100 magnification. Positive staining was detected in both the OC
and OC&dex-treated groups using alizarin red S (red for calcium)
and von Kossa staining (black/brown for calcium phosphate),
beginning on day 11 (Figures 1A and B). This staining increased
in intensity over time with the strongest staining observed in
the OC group. These findings were confirmed by quantitative
o-cresolphthalein calcium assay (Figure 1C). A statistically
significant increase in calcium was detected on days 21 (Po0.05)
and 28 (Po0.001) in the OC group compared with the control
group. Although an increase in calcium was also observed in the
OC&dex group over time, this was not found to be statistically
significant (P40.05). Raman microspectroscopy was used
to identify the mineral species being deposited (Figure 1D). The
Raman band observed at 960 cm1 in mineralising 4T1 samples
corresponds to a symmetric phosphate stretching mode, which is
indicative of HA (Nelson and Williamson, 1982).
Mineralisation potential of mammary cell lines is
associated with phenotype
The mineralisation potential of several additional murine and
human mammary cell lines was also investigated. These results are
summarised on Table 1. In addition to the 4T1 cell line, a highly
metastatic mammary subclone designated 4T1.2, which was
originally isolated from the parental 4T1 cells (Lelekakis et al,
1999), also produced HA in vitro. This occurred in response to
both the OC and OC&dex by day 14. Three human mammary
cell lines were also examined. Normal immortalised MCF10a cells
and the Hs578T cell line were not capable of mineralising under
the same experimental conditions. However, a more invasive
subclone designated Hs578Ts(i)8 (Hughes et al, 2008) produced
HA after 21 days growth with OC&dex treatment. The Raman band
at B960 cm1 detected in all mineralising samples is typical of
HA (Nelson and Williamson, 1982). The full width at half
height (FWHH) of the Raman phosphate peak was also measured,
as previous studies have shown that this reflects the carbonate
content of HA (Haka et al, 2002). The FWHH is narrower for the
Hs578Ts(i)8 mineralising samples (15.85±1.7 cm
1) compared
with that found in the 4T1 (23.89±3 cm1) and 4T1.2 (22.72±
2.5 cm1) cell lines. The data for each cell line included in Table 1
are outlined in the Supplementary Figures (see Supplementary
Figures S1–S4).
Mineralisation of 4T1 and 4T1.2 cells also occurs in vivo
Primary mammary tumours were produced by implanting 4T1 or
4T1.2 cells into the mammary fat pads of female BALB/c mice.
Serial sections of these tumours were stained with alizarin red S,
von Kossa (with nuclear fast red counterstain) and H&E to assess
mineralisation. One of the five 4T1 mammary tumours contained
calcifications and mineralisation was detected in five out of six
4T1.2 mammary tumours. A representative mineralising 4T1.2
mammary tumour is shown in Figure 2. Positive staining for
calcium (red; alizarin red S) and calcium phosphate (black/brown;
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Figure 1 Investigating the mineralisation potential of 4T1 cells. Representative Alizarin red S (A) and von Kossa (B) staining of 4T1 cells over time in
culture (original magnification  100) (n¼ 3). Scale bars represent 500 mm. (C) The calcium content of 4T1 cells as determined by the o-cresolphthalein
calcium assay and normalised to protein. Each point represents the mean amount of calcium measured in p.p.m. normalised to protein measured in mg,
±s.e.m., two-way ANOVA. *Po0.05 OC vs control on day 21. ***Po0.001 OC vs control on day 28. (D) Raman spectroscopy of mineralising 4T1 cells
grown in the OC for 28 days showing a peak at 960 cm1. Control¼ regular growth media. Osteogenic cocktail¼ regular growth media supplemented with
50mgml –1 ascorbic acid and 10mM bG. OC&dex¼ regular growth media supplemented with 50mgml – 1 ascorbic acid, 10mM bG and 107 M
dexamethasone.
Table 1 Summary of the mineralisation potential of a panel of mammary cell lines as assessed by alizarin red S, von Kossa staining, quantitative calcium
assay and Raman microspectroscopy
Cell line Cell phenotype
Mineralise
in vitro
Initial
histological
staining
Conditions
for
mineralisation
Raman
shift
(cm1)
FWHH
(cm1)
Mineral
species
MCF10a Human, immortalised, normal breast epithelial from
benign breast tissue of a woman with fibrocystic disease
No NA NA NA NA NA
Hs578T Human epithelial, mammary carcinoma of 74-year-old
Caucasian woman
No NA NA NA NA NA
Hs578Ts(i)8 A more invasive subclone of the Hs578T cells Yes Day 21 OC&dex 961.10±0.5 15.85±1.7 HA
4T1 Mouse, lung metastasising subclone from a spontaneous
mammary tumour
Yes Day 11 OC 960.84±0.7 22.45±3.4 HA
OC&dex 959.55±0.9 23.89±3.0 HA
4T1.2 Mouse, metastasising subclone isolated from the 4T1 Yes Day 14 OC 961.47±0.6 21.67±1.2 HA
cell line OC&dex 961.56±0.5 22.72±2.5 HA
Abbreviations: FWHH¼ full width at half height as determined by Raman spectroscopy; HA¼ hydroxyapatite; NA¼ not applicable; OC (osteogenic cocktail)¼ 50 mgml – 1
ascorbic acid and 10mM b-glycerophosphate; OC&dex¼OC including 107 M dexamethasone.
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von Kossa) was consistently observed in the same region of the
tumours between serial sections. Haematoxylin (purple) also
stained more intensely in the areas of calcifications.
Phosphate transport is required for mineralisation
of 4T1 cells
Phosphonoformic acid, a known inhibitor of the type II family of
sodium–phosphate cotransporters (Murer et al, 2004), was used to
investigate the role of phosphate transport in bG and Pi-induced
mineralisation of 4T1 cells. 4T1 cells stained positive for calcium
after treatment with either bG or Pi beginning on days 14
and 7, respectively (Figure 3A). However, the addition of PFA in
combination with either form of phosphate (bG&PFA or Pi&PFA)
inhibited mineralisation for up to 28 days. These results were
confirmed by von Kossa staining, as shown by representative
day 28 images (Figure 3B) and also by a quantitative calcium assay.
b-Glycerophosphate and Pi treatments resulted in a statistically
significant increase in calcium levels beginning on days 21 and 7,
respectively, (Po0.001; Figures 3C and D). In contrast, the calcium
levels of the bG&PFA and Pi&PFA groups remained comparable
to control levels over time.
ALP is required for mineralisation of 4T1 cells
The role of ALP was initially investigated using real-time RT–PCR
(Figure 4A). An increase in ALP mRNA expression was detected on
days 21 and 28 in mineralising OC-treated 4T1 cells (Po0.001).
In contrast, there was a general trend for decreased expression of
ALP mRNA in the mineralisation impaired OC&dex-treated 4T1
cells, which was statistically significant on days 7 and 14 (Po0.05).
The effect of exogenous ALP was also investigated. It was found
that when ALP was added to the OC, calcium levels were
consistently increased compared with the OC group on days 7
(Po0.05), 14 (Po0.01), 21 (Po0.01) and 28 (Po0.001; Figure 4B).
Next, the effect of levamisole, a known inhibitor of ALP, was
investigated in 4T1 cells. b-Glycerophosphate and Pi treatment
resulted in positive alizarin red S staining beginning on days 14
and 7, respectively, (Figure 4C). The addition of levamisole to bG
(bG&lev) inhibited alizarin red S staining for up to 28 days. In
contrast, levamisole had no effect on Pi-induced mineralisation, as
shown by positive alizarin red S staining beginning on day 7. These
findings were confirmed by von Kossa staining, as shown by
representative day 28 images (Figure 4D). These results were also
confirmed by quantitative calcium assays. Although an increase in
calcium levels was detectable in the bG-treated 4T1 cells over time
(Po0.001 vs control and bG&lev), no increase was detected in the
bG&lev group for up to 28 days (Figure 4E). Calcium levels
increased over time in the Pi-treated 4T1 cells (Po0.05 vs control)
and similar levels were detected in the Pi&lev group (Po0.01 vs
control). No statistical difference was detected between the Pi and
Pi&lev groups at any time point examined for up to 28 days
(P40.05; Figure 4F).
The effect of inhibitors of physiological mineralisation
on 4T1 mineralisation
The role of OPN was investigated using real-time RT–PCR
(Figure 5A). An increase in OPN mRNA expression was detected
on day 21 in mineralising OC-treated 4T1 cells (Po0.05) and on
day 11 in the mineralisation impaired OC&dex group (Po0.001).
The effect of exogenous OPN was also investigated in mineralising
4T1 cells using a quantitative calcium assay (Figure 5B), however,
the addition of 0.5 mgml–1 OPN to the OC (OC&OPN) resulted in
levels of calcium similar to the OC group by day 21 and no
differences were detected between these two groups (P40.05).
Similarly the exogenous addition of PPi, a known inhibitor of
physiological mineralisation, was found to have no effect on 4T1
cells (Figure 5C). An increase in calcium was detected in 4T1 cells
treated with the OC and 3.5 mM PPi (OC&PPi) compared with the
control group by day 28 (Po0.001; Figure 5C). These levels were
comparable to the elevated calcium levels of the OC group at all-
time points and no differences were detected between these two
groups (P40.05).
High endogenous ALP activity correlates with
mineralisation potential
Having found that exogenous PPi and OPN do not inhibit
mineralisation of 4T1 cells as expected, the endogenous levels of
ALP were investigated as a potential cause. An ALP stain was used
to visualise ALP activity in 4T1 cells grown for up to 14 days.
A pink colour indicates positive staining for ALP and representa-
tive images are shown in Figure 5D. Positive staining was observed
in the control samples on days 7 and 14. A further increase in
staining was detected in the OC group, whereas a decrease in ALP
staining was observed in the OC&dex group at both time points.
Alkaline phosphatase staining was also carried out on the MCF10a
cell line (Figure 5E), which was previously established as non-
mineralising under the same experimental conditions (Table 1).
No positive staining for ALP was observed for any treatment group
for up to 14 days in the MCF10a cells. These results were also
confirmed by a quantitative ALP assay (Figure 5F). By day 14, an
increase in ALP activity was found in the OC group compared with
the control group for the 4T1 cell line (Po0.001). In contrast, a
decrease in ALP activity was detected in the OC&dex group
on days 7 (Po0.05) and 14 (Po0.001). In direct comparison,
×100
Alizarin
red S
Von
Kossa
H&E
×400
200 m800 m
Figure 2 Mineralisation of mouse mammary tumours. Serial sections of
4T1 and 4T1.2 mammary fat pad tumours were stained using alizarin red S,
von Kossa (including nuclear fast red counterstain) and H&E. Mineralisation
was detected in five out of six primary 4T1.2 tumours and one out of five
primary 4T1 tumours. Representative images of 4T1.2 primary tumours are
shown. Scale bars represent 800 mm at  100 magnification and 200 mm at
 400 magnification. Alizarin red S and von Kossa staining are positive for
calcium (red) and calcium phosphate (black/brown), respectively. Haema-
toxylin also stained more intensely in areas of calcifications.
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the MCF10a cell line had little or no ALP activity for any treatment
group for up to 14 days.
bG, calcium and exogenous HA increase tumour cell
migration
Scratch wounds were made in monolayers of 4T1 cells and cell
migration was recorded in response to increasing concentrations
of bG, calcium (Ca2þ ), CO and HA. It was found that an increasing
number of cells migrated into the scratch areas over time for all
treatment groups. However, larger numbers of cells were observed
in the 10mM bG, 10mM Ca2þ and 72 mg cm–2 HA groups
compared with the control groups by 48 h (Figures 6A, B and D,
respectively). These results were found to be statistically
significant by quantitative analysis of wound closure using Scion
image software (Po0.01). In contrast, no significant changes were
detected for CO treatment for either 18 mg cm–2 or 72 mg cm–2 by
48 h (P40.05 vs control; Figure 6C).
DISCUSSION
Mammary microcalcifications are one of the most reliable
mammographic features of breast cancer and are often the sole
indicator of breast disease in its nonpalpable form. A recent study
has shown that the carbonate content of mammary microcalcifica-
tions composed of HA may be associated with lesion grade
(Baker et al, 2010). However, despite their value for the early
detection of breast cancer and potential prognostic importance,
the mechanisms by which mammary microcalcifications form are
unclear at best. It has remained uncertain whether they are
produced by an active cellular process or if calcifications are a sign
of cellular degeneration.
We have demonstrated here for the first time that mammary cell
lines are capable of mineralising in vitro. This has been shown in
detail for the mouse metastatic 4T1 cell line, which was found to
mineralise by day 11 when treated with an OC. Raman
microspectroscopy was used to identify the calcium species being
deposited by the 4T1 cells. The Raman band observed at 960 cm1
is indicative of the presence of HA, which is a clinically relevant
species of calcium that is associated with both benign and
malignant breast conditions (Bu¨sing et al, 1981; Radi, 1989; Haka
et al, 2002).
Mineralisation of additional mammary cell lines in the presence
of an OC was also confirmed, which included the metastastic
mouse mammary 4T1.2 cell line and the highly invasive human
mammary Hs578Ts(i)8 cell line. In contrast, the comparatively less
invasive Hs578T cells and the non-tumourigenic MCF10a cells
were not capable of mineralising under the same conditions. This
suggests that mineralisation potential in this in vitro model is
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Figure 3 The effect of 1mM PFA, a known inhibitor of Na-Pi co-transporters, on mineralisation of 4T1 cells. All images are viewed under the light
microscope at  100 magnification and the scale bars represent 500 mm (n¼ 3). (A) Alizarin red S staining of 4T1 cells treated with 1mM PFA. (B) Von
Kossa staining of 4T1 cells treated with 1mM PFA for 28 days. The effect of 1mM PFA on mineralisation of 4T1 cells as determined by the o-cresolphthalein
calcium assay is shown in (C) and (D). Each point represents the mean amount of calcium measured in p.p.m. normalised to protein measured in mg,
±s.e.m., two-way ANOVA. ***Po0.001 bG and Pi vs all other treatment groups at each time point. Ctl (control)¼ regular growth media. bG¼ 10mM bG.
PFA¼ 1mM PFA. bG&PFA¼ 10mM bG and 1mM PFA. Pi¼ 10mM Pi. Pi&PFA¼ 10mM Pi and 1mM PFA.
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associated with mammary cell phenotype, as only the tumouri-
genic mammary cells were capable of producing HA. In addition, a
narrower FWHH was found for the HA deposited by the
Hs578Ts(i)8 cells (15.9±1.7 cm
1) compared with all other
mineralising cell lines. Narrowing of the 960 cm1 phosphate
stretching peak has been associated with lower carbonate content
(Haka et al, 2002) and lower carbonate content with increasing
tumour grade (Baker et al, 2010), reflecting the highly invasive
nature of the Hs578Ts(i)8 cells. Haka et al (2002) previously
reported that type II microcalcifications occurring in benign breast
lesions had an average FWHH of 18.0±0.5 cm1, whereas deposits
in lesions diagnosed as DCIS had an average FWHH of
17.0±0.5 cm1. FWHH data for mineral resulting from murine
sources have not previously been reported but both mouse
cell lines (4T1 and 4T1.2) generated FWHH significantly higher
(21.7±1.2–23.9±3.0 cm1) than the human Hs578Ts(i)8 cell line
or previously reported data for human breast biopsies.
Osteogenic media was used throughout the in vitro experiments
because the addition of exogenous phosphate to investigate
mineralisation potential is routine in mineralisation studies of
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Figure 4 The role of ALP in 4T1 cell mineralisation. (A) The expression of ALP mRNA analysed using real-time RT–PCR. The results are expressed in
arbitrary units and normalised to the controls at each time point. Each point represents the mean±s.e.m., n¼ 3, two-way ANOVA. *Po0.05 OC&dex
vs control on days 7 and 14. ***Po0.001 OC vs control and OC&dex on days 21 and 28. (B) The effect of exogenous ALP, as determined by the
o-cresolphthalein calcium assay. Each point represents the mean amount of calcium measured in p.p.m. normalised to protein measured in mg, ±s.e.m.,
two-way ANOVA. *Po0.05 OC&ALP vs all groups on day 7, **Po0.01 OC&ALP vs all groups on days 14 and 21, ***Po0.001 OC&ALP vs all groups on
day 28. (C) Alizarin red S staining of 4T1 cells treated with 100 mM levamisole (lev) as viewed under the light microscope at  100 magnification. The scale
bar represents 500 mm. (D) Von Kossa staining of 4T1 cells treated with 100 mM lev for 28 days as viewed under the light microscope at  100 magnification.
The scale bar represents 500 mm. bG, Pi and Pi&lev samples stain positive for calcium phosphate (black) by day 28. No positive staining was observed in the
control, bG&lev and lev groups. The effect of lev on mineralisation of 4T1 cells as determined by the o-cresolphthalein calcium assays is shown in (E) and
(F). Each point represents the mean amount of calcium measured in p.p.m. normalised to protein measured in mg, ±s.e.m., two-way ANOVA. *Po0.05
Pi vs control on day 28, **Po0.01 Pi&lev vs control on day 28, ***Po0.001 bG vs control and bG&lev on day 28. Osteogenic cocktail¼ 50 mgml –1
ascorbic acid and 10mM bG. OC&dex¼OC including 107 M dexamethasone. ALP¼ 1Uml– 1 ALP. OC&ALP¼OC including 1Uml – 1 ALP. bG¼ 10mM
bG. bG&lev¼ 10mM bG and 100 mM lev. Lev¼ 100 mM lev. Pi¼ 10mM Pi. Pi&lev¼ 10mM Pi and 100 mM lev.
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numerous other pathologies, including osteoblasts and vascular
smooth muscle cells in vitro (Shioi et al, 1995; Coelho and
Fernandes, 2000). In the human body, phosphate is the most
abundant intracellular anion most commonly found in the form of
adenosine phosphates, (AMP, ADP and ATP) and in DNA and
RNA and can be released by the hydrolysis of ATP or ADP.
Consequently, it is not unreasonable to assume that in the early
tumour niche, rapidly proliferating populations of cells may be
exposed to physiologically localised high levels of phosphate. The
results of a small in vivo study are presented here, showing that
4T1 and 4T1.2 cells grown in the mammary fat pad of BALB/c mice
are capable of producing calcifications without any experimental
alteration to phosphate levels. The time required for mineralisation
of the 4T1 and 4T1.2 cells in vitro was relatively similar (11 vs
14 days, respectively), however, the detection of mineralisation in
the mammary fat pads in vivo differed, with microcalcifications
more common in the 4T1.2 tumours. The exact reasons for this are
unclear but may be related to the cells phenotype because the
4T1.2 cell line is a variant isolated from parental 4T1 cells through
single cell cloning and is known to develop overt metastases in
bone, lung and lymph nodes (Lelekakis et al, 1999). Unlike the 4T1
cell lines, the 4T1.2 cell lines have a high propensity to spread to
the auxiliary lymph nodes with metastasis thought to occur
through a lymphogenous route (Eckhardt et al, 2005). Their
increased tendency to mineralise may be another feature of their
aggressive phenotype. Never the less both cell lines 4T1 and 4T1.2
are capable of mineralising in vivo in the absence of any exogenous
factors or experimental alternation to physiological phosphate
levels. This demonstrates an innate ability to produce mammary
microcalcifications during the course of tumour development.
This finding also supports our in vitro work and demonstrates that
mineralisation is not simply due to the presence of cell culture
medium constituents or a phenomenon resulting from prolonged
monolayer culture.
Dexamethasone, a synthetic glucocorticoid, was also investi-
gated as it has been shown to enhance the mineralisation of certain
bone-like cells (Maniatopoulos et al, 1988; Coelho and Fernandes,
2000). As the mineralisation potential of mammary cells in vitro
was previously unexplored, two versions of the OC (with and
without dexamethasone) were investigated in order to determine
the optimum conditions for mineralisation. We have shown that
dexamethasone inhibits mineralisation of both the mouse 4T1 and
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Figure 5 The effect of known inhibitors of physiological mineralisation on 4T1 cells and the influence of endogenous ALP activity. (A) The expression of
OPN mRNA analysed using real-time RT–PCR. The results are expressed in arbitrary units and normalised to the controls at each time point. Each point
represents the mean±s.e.m., n¼ 3, two-way ANOVA. *Po0.05 OC vs control and OC&dex on day 21. ***Po0.001 OC&dex vs control and OC on
day 11. (B) The effect of exogenous OPN on mineralisation of 4T1 cells, as determined by the o-cresolphthalein calcium assay. Each point represents the
mean amount of calcium measured in p.p.m. normalised to protein measured in mg,±s.e.m., one-way ANOVA. **Po0.01 OC and OC&OPN vs control
on day 21. (C) The effect of PPi on mineralisation of 4T1 cells, as determined by the o-cresolphthalein calcium assay. Each point represents the mean
amount of calcium measured in p.p.m. normalised to protein measured in mg, ±s.e.m., two-way ANOVA. **Po0.01 OC vs control and PPi on day 28,
***Po0.001 OC&PPi vs control and PPi on day 28. (D) An ALP stain carried out on 4T1 cells, as observed under the light microscope at  100
magnification. The scale bar represents 500 mm. Positive staining for ALP (pink) is observed on days 7 and 14 in the control (Ctl), OC and OC&dex groups.
(E) An ALP stain carried out on MCF10a cells, as observed under the light microscope at  100 magnification. The scale bar represents 500 mm. No positive
staining for ALP was observed for any treatment group at any time point. (F) A comparison of ALP activity in 4T1 and MCF10a cells. The results are
expressed in ALP (pg) normalised to protein (mg). Each point represents the mean±s.e.m., two-way ANOVA. *Po0.05 OC&dex vs control on day 7 in
4T1 cells, ***Po0.001 OC and OC&dex vs control on day 14 in 4T1 cells. Osteogenic cocktail¼ 50 mgml –1 ascorbic acid and 10mM bG. OC&dex¼OC
including 107 M dexamethasone. OC&PPi¼OC and 3.5 mM pyrophosphate. PPi¼ 3.5 mM pyrophosphate. OC&OPN¼OC and 0.5 mgml –1 OPN.
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4T1.2 cell lines. In contrast, the presence of dexamethasone in the
OC is required for the mineralisation of the human Hs578Ts(i)8
cell line. This species-specific effect has also been observed in
studies of in vitro mineralisation using osteoblasts. Dexametha-
sone enhances mineralisation of human bone marrow cells
(Coelho and Fernandes, 2000), whereas dexamethasone inhibits
mineralisation of the mouse osteoblast MC3T3-E1 cell line in vitro
(Lian et al, 1997). It has been suggested that the differing effect of
dexamethasone may depend on the stage of osteoblast maturation
of the cell lines investigated (Lian et al, 1997). In addition, the
reason for the species-specific effect of dexamethasone may be
due to differences in the metabolism of dexamethasone between
human and mouse cells, which results in differing major
metabolites (Tomlinson et al, 1997). These different metabolites
could potentially have varying effects on cell signalling and gene
transcription associated with mineralisation.
Using the established in vitro model of mammary mineralisa-
tion, the molecular mechanisms involved in this process were
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Figure 6 Investigating the effect of increasing concentrations of bG, calcium (Ca2þ ), CO and HA on 4T1 cell migration using a scratch wound assay.
(A) The scratch wound assay of 4T1 cells treated with bG. By 48 h, an increase in cell migration is observed with 10mM bG treatment compared with the
control group (ctl; growth media containing 0.5% FBS), which was found to be statistically significant when quantified using Scion image software. (B) The
scratch wound assay of 4T1 cells treated with increasing concentrations of calcium. By 48 h, an increase in cell migration is observed with 10mM Ca2þ
treatment compared with the 1.8mM Ca2þ group (growth media containing 0.5% FBS), which was found to be statistically significant when quantified using
Scion image software. (C) The scratch wound assay of 4T1 cells treated with increasing concentrations of CO. No significant differences in cell migration
were detected between the different treatment groups at any time point. (D) The scratch wound assay of 4T1 cells treated with increasing concentrations of
HA. An increase in cell migration is observed for the 72mg cm–2 HA-treated cells compared with the control group by 48 h, which was confirmed as
statistically significant when quantified using Scion image software. All images are viewed under a light microscope at  100 magnification at 0, 24 and 48 h
(n¼ 3). The scale bars represent 500 mm. For quantification, each point represents the mean percentage scratch wound closure±s.e.m., two-way ANOVA.
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investigated. The role of phosphate transport was studied using
PFA, a known inhibitor of the type II family of sodium-phosphate
(Na-Pi) cotransporters (Murer et al, 2004). Inhibition of these
Na-Pi cotransporters using PFA completely abolished both bG-
induced and Pi-induced mineralisation of 4T1 cells. This indicates
that, regardless of the source, internalisation of phosphate is
essential for 4T1 mineralisation to occur in this model. The
transport of phosphate across a membrane by a phosphate pump
suggests that an active regulated process is at work and that the
mineralisation observed is not simply due to precipitation within
the media or the result of necrotic debris. In addition, it has been
reported that the expression of the NaPi-IIb cotransporter is
elevated in breast cancer tissue in comparison with normal tissue
(Chen et al, 2010). No other researchers have investigated
the involvement of these transporter pumps in mammary cell
mineralisation, however, upregulation of Na-Pi cotransporters in
mammary epithelial cells by disease state may facilitate localised
mineralisation even when serum phosphate levels are in the
normal physiological range.
The role of ALP was also investigated, as this enzyme has a well-
documented role in physiological HA production (Owen et al,
1990; Orimo, 2010). An increase in ALP mRNA was detected in the
mineralising OC-treated 4T1 cells and the exogenous addition of
ALP was found to enhance 4T1 cell mineralisation. It was also
found that levamisole, which is a known inhibitor of ALP, inhibits
bG-induced mineralisation, but not Pi-induced mineralisation of
4T1 cells. This suggests that ALP may have a similar function in
mineralising mammary cell lines as observed for osteoblasts.
Alkaline phosphatase is thought to hydrolyse organic phosphate,
liberating Pi, which can be used by cells to create HA (Robison,
1923; Simao et al, 2007). When ALP function is inhibited by
levamisole treatment of the 4T1 cells, no bG-induced mineralisa-
tion takes place. This is likely due to the impaired production of
Pi from bG. In contrast, impaired ALP function has no impact on
Pi-induced mineralisation, as Pi is already freely available to be
used by the cells for HA production. This would also explain why
mineralisation is consistently detected at earlier time points for the
Pi-treated cells, as hydrolysis of bG is thought to be time
dependent.
The potential role of OPN was investigated in our in vitro model
of mammary cell mineralisation, as this phosphoprotein is highly
expressed in bone and is known to be upregulated during bone
formation (Chen et al, 1992; Standal et al, 2004). Increased
expression of OPN has also been reported in breast tumours
containing microcalcifications (Bellahcene and Castronovo, 1995).
The endogenous expression of OPN mRNA was found to be
upregulated in the mineralising OC group on day 21. This provides
further evidence that mammary cells mineralise in a regulated
manner similar to osteoblasts. In addition, an increase in OPN
mRNA was detected on day 11 in the OC&dex group. This may
contribute to the diminished levels of mineralisation observed in
the OC&dex group compared with the OC. Osteopontin is thought
to negatively regulate mineralisation by binding to and preventing
further HA crystal growth (Boskey et al, 1993; Gericke et al, 2005;
Jahnen-Dechent et al, 2008). The relatively early increased
expression of OPN mRNA coupled with the trend for decreased
ALP mRNA expression in the OC&dex group may explain why less
mineralisation was detected in this treatment group.
The role of OPN was investigated further by examining the effect
of exogenous OPN on 4T1 mineralisation, as this is known to
inhibit mineralisation of osteoblasts in vitro (Boskey et al, 1993;
Addison et al, 2007). However, the exogenous addition of OPN had
no effect on 4T1 cell mineralisation when added to the OC.
Similarly, exogenous treatment with PPi, another known inhibitor
of osteoblast mineralisation (Addison et al, 2007), had no effect
on 4T1 mineralisation. These results indicate that the process
of mammary mineralisation may not be completely identical to
that of physiological mineralisation. We hypothesised that this
observation may be due to high endogenous level of ALP, as
ALP has been shown to remove the inhibitory effect of both OPN
and pyrophosphate through dephosphorylation and hydrolysis,
respectively. Osteopontin is only active in its phosphorylated form
(Boskey et al, 1993; Hunter et al, 1994; Keykhosravani et al, 2005)
and pyrophosphate can be hydrolysed to Pi, which removes its
inhibitory effect (Lomashvili et al, 2004; Addison et al, 2007;
Simao et al, 2007). Therefore, an ALP stain and assay were used to
examine the endogenous ALP activity in the mineralising 4T1 cell
line compared with the non-mineralising MCF10a cell line. As
predicted, comparatively high levels of ALP activity were
detectable even in the control 4T1 cells, whereas little or no ALP
activity was detectable in the MCF10a cell line for any treatment
investigated. Additional increases in ALP activity were observed in
the 4T1 cells in response to the OC. Therefore, enhanced
expression of already high endogenous levels of ALP could remove
the inhibitory effects of OPN and pyrophosphate in this in vitro
model.
The effect of the in vitro culture conditions that resulted in
mineralisation were also investigated in relation to cell migration.
Using scratch wound assays it was found that 10mM bG enhanced
migration of the 4T1 cells by 40% after 48 h of treatment compared
with the control group. As microcalcifications may form in
response to locally high concentrations of calcium, increasing
concentrations of calcium were also examined. In all, 10mM
calcium was found to increase migration of 4T1 cells by B30%
after 48-h treatment in comparison with the control group. These
data suggest that the microenvironment or niche conditions
preceding, and ultimately leading to, mammary mineralisation
may promote migration of 4T1 cells. Next, the functional effects of
exogenous crystallised CO and HA on 4T1 cell migration were
investigated. It was found that CO crystals of up to 72 mg cm–2
have no effect on cell migration for up to 48 h of treatment.
In contrast, after 48 h of treatment with 72 mg cm–2 of HA crystals,
4T1 cell migration increased by 20% in comparison with
the control group. As increasing concentrations of phosphate or
calcium had slightly more pronounced migratory effects than the
addition of exogenous crystallised HA, it is possible that the pre-
mineralisation phase is of most biological significance. Miner-
alisation will result in sequestering of calcium and phosphate,
which may be chronically released and its effects may be more
pronounced in an assay carried out over a much longer time
period. The increase in cell migration observed for HA treatment,
but not seen with CO, lends weight to the theory that HA and the
conditions, which precede its deposition may have functional
biological consequences within the tumour microenvironment.
These findings suggest that deposited HA may be capable of
stimulating migration of the surrounding cells within the tumour
microenvironment, which could contribute to breast cancer
progression. We have previously reported that HA treatment of
several mammary cell lines upregulates the production of MMPs
(Morgan et al, 2001), which are known to contribute to breast
cancer invasion of surrounding tissue (Lochter and Bissell, 1999).
Therefore, the presence of HA within the tumour microenviron-
ment could contribute to breast cancer progression and ultimately
metastasis by producing MMPs to degrade the basement
membrane and enhance the migration of cells to the surroundings
tissues.
Based on the results discussed in this paper, we put forward a
mechanism for in vitro 4T1 mammary cell mineralisation
(Figure 7). We suggest that ALP on the surface of mammary cells
hydrolyses bG to glycerol and Pi. The Pi produced may then be
transported into the mammary cells by the type II family of Na-Pi
cotransporters. Once inside the cell, the Pi could combine with any
available sources of calcium to produce HA crystals. Mammary
cells have an innate ability to concentrate calcium ions, as this
occurs naturally to allow lactation to take place (Virk et al, 1985;
VanHouten et al, 2007). Hydroxyapatite would then leave the cells
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by an as of yet unknown mechanism. Osteopontin and PPi within
the extracellular matrix have no effect on limiting crystal growth,
possibly due to the upregulation of ALP. Alkaline phosphatase may
act by dephosphorylation of OPN and hydrolysing PPi to Pi, which
could be subsequently incorporated in growing HA crystals.
Therefore, we propose that an imbalance of these regulators of
physiological mineralisation within the tumour microenvironment
may be responsible for the formation of pathological mammary
microcalcifications. Hydroxyapatite and the biochemical condi-
tions, which initiate its deposition could then enhance the
migration of the surrounding mammary cells. In addition,
the osteomimicry capabilities of the mammary cells may also
contribute to their ability to metastasise to bone once in the
circulation, as they would possess an innate ability to survive
within the bone microenvironment.
One of the models most notable characteristic is that the cells
generate HA, a calcium species, which is found in human clinical
samples. Under the conditions examined in vitro only the more
tumourigenic cell lines were capable of mineralising, suggesting
that our in vitro model and the proposed mechanism may be most
useful for the study of calcium deposition associated with
malignancy of the breast. As with all in vitro models there are
limitations in the recapitulation of the complex interactions, which
may take place in an in vivo scenario. Despite this our cell line
model has the advantage of providing an unlimited source of
homogenous material, and is free of potential contaminating
stromal cells, offering the opportunity to perform reproducible
mechanistic experiments in a controlled environment. Although
the transposability to tumours of results obtained from cell lines
universally remains a matter of debate this model represents a
starting point in an area, which was previously unexplored.
This work offers insights into the process of malignant
mineralisation in breast tissue and will ultimately pave the way
for a more complete understanding of the complex relationships
between the mineral, the microenvironment and the differentiation
state of the cells, which deposit them. As more breast cancer cases
are being detected in their pre-palpable stage, largely through the
presence of mammary microcalcifications, it is imperative that
current research efforts reflect these developments and focus on
understanding the biology underlying one of the most reliable
markers of preclinical breast cancer.
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